(Reuters) - The Plavix ruling by a U.S. judge on Tuesday handed a major victory to Bristol-Myers and Sanofi, which are partners on the multibillion-dollar blood clot-preventing drug. The long-awaited ruling blocks sales of generic Plavix.
The trans-Atlantic takeover would boost Paris-based Sanofi's weakened new drug pipeline and allow significant cost savings. But serious obstacles remain to any deal, analysts said, such as differences between top executives at the firms.
Read more at Reuters.com Business News
The trans-Atlantic takeover would boost Paris-based Sanofi's weakened new drug pipeline and allow significant cost savings. But serious obstacles remain to any deal, analysts said, such as differences between top executives at the firms.
Read more at Reuters.com Business News
No comments:
Post a Comment